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Introduction
Since  the  pioneering  isolation  and  culture  of  human 
embryonic  stem  cells  over  a  decade  ago,  a  new  era  of 
clinical promise in regenerative medicine has emerged. 
Stem cell research will improve our ability to prevent and 
cure disease by providing cells for organ transplantation 
and  cell  therapies.  It  will  also  be  used  to  create  a 
successful model system for drug discovery, including the 
development of new testing methods for drug efficacy, 
toxicity and safety, and provide a deeper understanding 
of the processes of human cell differentiation and develop­
ment for the treatment of diseases such as cancer [1].
Given  the  scientific  potential  of  the  field,  stem  cell 
banks are increasingly seen as an essential resource of 
biological  materials  for  both  basic  and  translational 
research.  Stem  cell  banks  and  registries  support  trans­
national access to quality­controlled and ethically sourced 
stem  cell  lines  from  different  origins  and  of  varying 
grades ­ for example, research versus clinical. They are also 
the  ‘de  facto’  depositories  of  ‘biological  standards’  [2]. 
According  to  the  Organisation  for  Economic  Co­
operation  and  Development,  advances  in  regenerative 
medicine and stem cells are leading to the development 
of a bio  economy: ‘a world where biotechnology contri­
butes  to  a  significant  share  of  economic  output’  [3]. 
Conse  quently, stem cell banks are destined to constitute 
a pillar of the bioeconomy of many countries.
International  initiatives  are  emerging  to  address 
harmonization  and  standardization  processes  for  stem 
cell research and banking; these include the International 
Society for Stem Cell Research (ISSCR) and the Inter­
national  Stem  Cell  Banking  Initiative  (ISCBI).  Until 
recently,  these  efforts  adopted  an  ‘embryo­centric’ 
approach,  leaving  behind  other  timely  and  promising 
sources, such as induced pluripotent stem (iPs) cells or 
those  derived  from  placentas  and  umbilical  cords, 
among  others.  Today,  the  size  and  the  scope  of  the 
collections are growing, as witnessed by the increasing 
number of registries of disease biological samples and 
iPs cell lines [4­6].
Stem  cell  banks  are  poised  to  maintain  internal 
consistency with respect to policy frameworks relating to 
the permissibility of conducting stem cell research [7]. 
However, due to the heterogeneous nature of these policy 
approaches and their lack of interoperability, uncer  tain­
ties remain on the legality of certain practices, such as, 
for  instance,  material  derivation  and  distribution  [8]. 
Similarly, uncertainties exist with respect to the ethics of 
both  national  and  cross­border  material  and  data  use. 
Currently, the self­regulatory approaches applied to the 
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The term ‘stem cell bank’ itself can refer to a number of 
different  levels  and  types  of  operations,  as  well  as 
institutions [10]. It can refer to a centralized institute that 
provides  cell  stocks  for  research  (for  example,  the 
Singapore Stem Cell Bank), a national supply centre, or a 
repository of human embryonic stem cells (hESCs) for a 
broad  range  of  researchers  (for  example,  the  Indian 
National Centre for Stem Cell Science). Similarly, stem 
cell banks range from public banks, as for instance the 
UK Stem Cell Bank and the Spanish National Stem Cell 
Bank,  to  institutional  banks,  such  as  the  Stem  Cell 
Research Centre, Kyoto University, Japan, and commer­
cial  banks  (for  example,  the  WISC  Bank  of  WiCell, 
Madison, WI, USA). Finally, the term ‘stem cell bank’ can 
also  refer  to  registries  or  databases  cataloguing  or 
documenting the scientific and ethical provenance of the 
stem cell lines; examples of registries include the Euro­
pean  Human  Embryonic  Stem  Cell  Registry  and  the 
UMass International Stem Cell Registry. Here, we use the 
term  ‘stem  cell  bank’  to  encompass  the  wide  range  of 
institutions referred to above.
Biobanking has been defined as ‘structured resources 
that can be used for the purpose of genetic research and 
which  include:  (a)  human  biological  materials  and/or 
information generated from the analysis of the same, and 
(b)  extensive  associated  information’  [11].  Even  within 
biobanking,  distinctions  remain  between  those  studies 
that are populational or retrospective, and those that use 
clinical  residual  tissues  [11].  Population  biobanks  are 
usually longitudinal and serve as resources for future un­
specified research. Retrospective research is increasingly 
using collections of residual samples leftover after medical 
care  or  from  pathology  archives.  To  a  lesser  extent, 
anonymized collections (irreversibly delinked) can also be 
of interest as controls. ‘Size matters’ [12] in understanding 
gene­environment  interactions  and  normal  genomic 
variation,  and  because  of  this  there  has  been  a 
phenomenal growth in biobanking. Indeed, in 2009, Time 
magazine [13] recognized ‘biobanks’ as one of the ‘top 10 
ideas changing the world’.
Like biobanks, stem cell banks have as a core objective to 
avoid redundancy in research projects and to eliminate the 
need for the collection and derivation of additional human 
materials. They aim to ensure the quality, availability and 
ethical  provenance  of  tissues,  cells  or  embryos  used  for 
research and eventual therapies. It is interesting to note that 
tissue banks and stem cell banks are encountering issues 
similar to those found in international biobanking generally; 
these  issues  include  institutional  governance,  respect  of 
autonomy and privacy, uses of samples, and so on. Both face 
similar challenges of ensuring safety through traceability, 
while protecting the autonomy and privacy of donors.
It  is  in  this  tension  between  traceability  and  privacy 
that  some  of  the  lessons  learned  in  the  human  tissue 
banking field (particularly since the advent of population 
biobanking)  may  prove  to  be  instructive  for  stem  cell 
banking. Some banking issues remain particular to the 
field of stem cells, such as those posed by the develop­
ment of innovative sources and uses of stem cell lines, 
including embryonic, adult and cord blood, and placenta 
[8].  Nevertheless,  issues  relating  to  the  legitimacy, 
indepen  dence, transparency and governance of banking 
activities  are  present  in  both.  These  issues  with  their 
concomitant challenges are even more critical in the case 
of stem cell banks, given the political, social and ethical 
controversies  that  have  historically  surrounded  embry­
onic stem cell research.
Of  particular  importance  are  the  ethical  and  policy 
issues surrounding recent scientific advances pertaining 
to non­embryonic sources of stem cell lines (that is, iPS 
cells). The discovery of iPS cells was considered to be a 
scientific breakthrough that would eliminate the major 
socioethical  and  policy  concerns  that  have  beset 
embryonic sources [14]. It has been argued that iPS cells 
do not pose major ethical or legal concerns, and that they 
should  be  regulated  under  the  general  rules  for  tissue 
donation [15,16]. However, these arguments are far from 
being  valid.  For  example,  the  ‘virtual  genetic  identity 
between iPS and donor cells raises particular concerns 
regarding respect for donors’ [17], in terms of protecting 
their  autonomy  and  consent,  as  well  as  privacy  and 
confidentiality;  the  latter  is  of  particular  importance 
given  the  potential  traceability  of  stem  cell  lines  [18]. 
Likewise,  the  possibility  of  reprogramming  such  cells 
back to their origins [19] re­introduces the ‘embryonic’ 
issues. Consequently, appropriate mechanisms and ethical 
and  legal  approaches  to  solve  challenges  related  to 
informed consent, privacy and confidentiality, commer­
cialization, and the safety of human research participants 
are yet to be defined for stem cell banking.
While certain ethical and legal concerns are specific to 
the  nature  of  stem  cells  (especially  hESCs),  stem  cell 
banking could do well to examine the approaches fos­
tered by tissue banking generally. Indeed, the past decade 
has  seen  a  move  to  simplify  and  harmonize  biological 
tissue and data banking so as to foster international inter­
operability  [20].  In  particular,  the  issues  of  consent, 
traceability and, more recently, return of results illustrate 
not only commonalities but the opportunity for stem cell 
banking to appreciate the lessons learned in biobanking 
generally.
Harmonization and international cooperation
Human tissue banks and related international initiatives, 
such as the Organisation for Economic Co­operation and 
Development  [11,21]  and  the  International  Society  for 
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addressed issues of safety and harmonization, while stem 
cell  banks,  beginning  with  the  fundamental  step  of 
registries  [23],  have  only  recently  joined  this  effort. 
Indeed, the expansion of stem cell banking efforts was 
not initially followed by a discussion about the appro­
priate mechanisms for domestic and international bank­
ing governance, as well as the need for both harmoni­
zation and international collaboration.
A recent comprehensive study analyzing harmonization 
and  networking  practices  and  trends  in  European 
biobanks  [24]  identified  the  lack  of  concerted  efforts, 
together with heterogeneous policy approaches and prac­
tices, as threats to their sustainability. When collabora­
tion and the sharing of samples and data are jeopardized, 
then  the  raison  d’être  of  the  biobank  is  also  put  in 
jeopardy. In the context of embryonic stem cell banking, 
our  previous  research  also  identified  similar  gaps  and 
situations where the lack of concerted effort is impeding 
transnational and translational research [23]. All of this is 
in  striking  contrast  with  current  population  studies 
involving biobanking; these are rapidly becoming inter­
operable [25] and, despite different legal regimes, inter­
national collaborative research is becoming a reality [26].
In the stem cell field, international initiatives are now 
emerging to address harmonization and standardization 
processes for research and banking. These initiatives, like 
their population biobank counterparts, share the vision 
of scientific research as a global enterprise. For instance, 
the ISCBI of the International Stem Cell Forum has been 
established with the goal of creating a set of international 
minimum  standards  (or  best  practice  guidelines)  for 
banking, characterization and testing of stem cell lines. 
The mission of the ISCBI is to create a solid scientific and 
ethical framework for international stem cell banking and 
research.  Thus,  a  major  objective  of  the  ISCBI  is  the 
establishment of a global and interoperable network of 
stem cell banks [27].
In  2008,  the  ISCBI  adopted  its  first  best  practices 
guidelines:  the  Consensus  Guidance  for  Banking  and 
Supply  of  Human  Embryonic  Stem  Cell  Lines  for 
Research Purposes [28], which standardizes best practice 
for  the  banking,  testing  and  distribution  of  hESCs  for 
research purposes. The guidance covers a wide range of 
processes  involved  in  stem  cell  banking,  including 
procure  ment of cell lines, cell banking procedures and 
documentation,  cell  banking  quality  control,  and  the 
process of releasing cell banks. It also establishes tech­
nical  requirements,  such  as  release  criteria,  microbio­
logical  testing,  cell  characterization  and  shipment  of 
cells,  and  it  addresses  core  ethical  issues,  such  as  in­
formed consent, oversight and licensing, and traceability 
and  documentation  of  cell  provenance.  In  2011,  the 
ISCBI  is  expected  to  launch  similar  best  practice 
guidelines directed at clinical grade embryonic stem cell 
lines.
Other  important  harmonization  and  standardization 
efforts  are  carried  out  by  the  European  Human 
Embryonic  Stem  Cell  Registry,  the  ISSCR  (Registry  of 
Human Embryonic Stem Cell Line Provenance) and the 
International  Stem  Cell  Registry  (ISCR)  of  hESC  lines 
and iPs cell lines launched by the University of Massa­
chusetts  Medical  School.  These  registries  have  been 
established  with  the  goal  of  systematically  collecting, 
organizing and disseminating cell­line­specific informa­
tion  [23].  Their  mission  highlights  the  significance  of 
international cooperation in the field.
Informed consent
While  certain  issues  arise  in  the  fields  of  stem  cell 
banking  and  of  traditional  biobanking  (collection  of 
biological specimens such as DNA, tissues, bone marrow, 
and  so  on),  the  fields  themselves  have  developed  in 
parallel, seemingly without much policy cross­fertiliza­
tion.  For  a  decade,  stem  cell  banking  has  long  been 
dominated by the ‘status’ of the embryo issue, and tissue 
banking by the issue of the validity of the broad consent. 
However, both have moved on, the former not only due 
to  the  arrival  of  iPS  cells,  but  also  increasing  liberal 
attitudes  towards  research  involving  embryos,  and  the 
latter  due  to  acceptance  of  broad  consent  because  of 
heightened  security  and  governance  mechanisms 
ensuring respect for the altruistic citizen donors involved 
in large population studies.
However, for both contemporary and emerging sources 
of stem cells, and their prospective or retrospective use, 
the need to resolve important issues has intensified. The 
ethical and policy landscape remains to be charted [29] 
even when dealing with core ethical principles [30], such 
as  autonomy  (informed  consent,  right  to  withdrawal), 
respect  for  privacy  and  confidentiality  (for  example, 
protection of donor identity given the potential for trace­
ability of stem cell lines), and the non­commercialization 
of human reproductive materials (translated in restric­
tions on monetary compensation for gamete and tissue 
donation).
While  informed  consent  requirements  for  stem  cell 
derivation, use and banking have evolved along with the 
pace of scientific developments, significant policy varia­
tions across jurisdictions still exist for both somatic and 
embryonic sources [31]. Moreover, most consent require­
ments across jurisdictions and policy approaches still do 
not  include  consent  for  international  exchange  and 
research use [32].
Earlier  consent  requirements  for  the  derivation  of 
embryonic stem cell lines were often either too general or 
too specific [33], or did not foresee some research uses 
[34].  The  current  policy  trend  is  to  seek  an  informed 
Knoppers and Isasi Genome Medicine 2010, 2:73 
http://genomemedicine.com/content/2/10/73
Page 3 of 7consent for stem cell research, in some cases requiring 
consent for stem cell research from both gamete donors, 
and  it  increasingly  includes  the  option  to  consent  for 
future unspecified research uses [35]. Although consent 
policies  are  evolving,  the  underlying  rationale  for 
respecting  such  a  broad  consent  (that  is,  respect  for 
autonomy) has not been elucidated. This may be the only 
plausible  explanation  for  recent  decisions  by  funding 
organizations in some jurisdictions [36].
In contrast, populational resources are longitudinal and 
open, adding socio­demographic and environmental data 
over time via re­contact with participants. Created for 
future unspecified research, these resources, as already 
mentioned,  balance  the  broad  consent  obtained  by 
offering  increased  security  and  governance  [9].  Retro­
spective research using already collected tissue and data 
obtains  an  ethics  waiver,  thereby  avoiding  the  require­
ment  of  re­consent,  or  it  re­contacts  and  re­consents 
participants where feasible, or, finally, it anonymizes the 
data  and  samples,  thereby  limiting  their  usefulness  to 
meta­analyses  or  as  controls  [37].  Clinical  residual 
samples  are  increasingly  used  for  research  under  a 
notification system for incoming patients with a possible 
opt­out [38]. Traditional disease­specific research usually 
limits consent to the disease in question or to ‘related’ 
conditions.  Absent  anonymization,  in  all  types  of  bio­
bank  ing,  traceability  is  possible  and  international 
research and exchange is foreseen in the consent process. 
The international exchange of samples is predicated on 
obtaining  patient  information.  Hence,  traceability  is 
essential for the above to occur. Complete anonymization 
impedes the utility of such samples as it is impossible to 
trace the sample back to the donor.
Traceability and identifiability
Across this typology of tissue banking, and in conformity 
with the consent or ethics waiver, researchers agree to 
respect  privacy  and  not  to  attempt  to  re­identify  the 
donors.  This  obligation  forms  part  of  the  informed 
consent process, and is also part of the material transfer 
agreement  for  access  by  researchers  to  biobanks. 
Together with the increasing trend to require biological 
resources to publish short summaries of the protocols of 
researchers accessing such public resources, transparency 
is  ensured.  This  also  underscores  the  commitment  to 
donors  to  respect  their  consent  and  provides  public 
feedback  and  monitoring.  In  short,  identifiability  and 
traceability are not a serious threat to privacy, but rather 
an assurance of safety and accountability.
Indeed, traceability of samples constitutes one of the 
cornerstones of stem cell banking. Traceability has been 
defined as ‘tracking an individual through their medical 
history’  [39].  It  promotes  safety  and  quality,  but  also 
provides a system for the tracking of handling and storage 
conditions  and  of  ethical  provenance.  In  this  sense, 
‘biological’ traceability is the equivalent of the personal 
data: tracing that identifiability provides via the coding of 
samples and data. Despite the fact that traceability is an 
essential component of the quality management system 
of stem cell banks [39], the regulations adopted in some 
jurisdictions  make  traceability  unfeasible.  For  instance, 
under Canadian policy [40], the requirement to anony­
mize  all  cell  lines  (except  autologous  cells)  prevents 
tracing back from cell to donor and limits the utility of 
such cell lines.
Identifiability can be defined as ‘information that may 
reasonably be expected to identify an individual, alone or 
in  combination  with  other  available  information’  [41]. 
Even while employing coding, encryption, firewalls and 
other security mechanisms, it serves to respect privacy 
while ensuring that the accompanying clinical phenotypic 
data can be updated and validated. Also, with coding and 
thus potential identifiability, should the donors of data 
and samples wish to withdraw their samples or data, this 
fundamental right can be respected. In this it stands in 
contrast  to  anonymization,  which,  while  ethically  and 
legally expedient by avoiding the possibility of re­identi­
fiability or traceability, ultimately limits eventual safety 
and  scientific  usefulness.  Traceability  serves  to  ensure 
quality  validation  while,  for  biobanks,  identifiability 
allows for the ongoing updating of clinical data, making 
the samples more interesting for research. Withdrawal of 
donors of stem cells or of research participants is also 
possible. In the field of biobanking, novel methods and 
associated  tools  permitting  individual  identification  in 
publicly  accessible  SNP  databases  have  become  a 
debatable issue [42,43]. There is concern that established 
safeguards to protect the identities of donors could be 
insufficient [44].
The move towards open access, to at least aggregate 
data and to deposit data into public domain databases 
(for example, PubMed) as well as into controlled access 
databases, is becoming both ethically sanctioned and a 
condition of funding of biobanks. Thus, while recently, as 
mentioned  above,  fears  of  re­identifiability  led  to  an 
increase  in  controlled  access  databases  as  opposed  to 
open  access,  this  may  change  as  mechanisms  and 
algorithms are appearing that ostensibly not only serve to 
respond to the difficulty of transferring and sharing the 
sheer amount of data available, but also to shield against 
re­identifiability  by  permitting  local  preparation  of 
phenotypic data prior to transfer [45]. We maintain that 
identifiability  and  traceability  serve  to  strengthen  the 
scientific validity and utility of research involving human 
tissues and can do the same for stem cell banking.
However, it should be mentioned that, in the context of 
embryonic  stem  cell  research,  the  possibility  of  donor 
identification  based  solely  on  the  hESC  is  extremely 
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directly to the genotype of the individuals who donated 
the embryo (International Stem Cell Forum Ethics Work­
ing Party, unpublished work). Consequently, and follow­
ing  a  proportional  approach  to  privacy  (Inter  national 
Stem  Cell  Forum  Ethics  Working  Party,  unpublished 
work) [46], the publication of all genotypic information 
for these lines in banks and registries does not seem to 
pose a threat to the privacy and confidentiality of donors. 
For other sources of stem cell lines (for example, iPs cells) 
and,  given  the  considerations  mentioned  above,  the 
potential for donor identifiability also seems remote.
Return of results
Lessons learned on the issue of return of results in the 
biobanking  domain  may  be  particularly  instructive  for 
stem  cell  biobanking.  However,  the  biobanking  field  is 
awash with contradictions and confusion [47]. This may 
be  due,  in  part,  to  the  need  for  clarification  in  the 
terminology  used.  Feedback  usually  refers  to  either 
immediate personal communication upon enrolment of 
research participants or to the availability of aggregate 
general  results  via  websites  or  newsletters  upon  the 
completion  of  research.  In  between  these  particular 
points  in  time,  distinctions  should  be  drawn  between 
research  results  and  incidental  findings  since  context 
matters [48].
If  enrolment  in  a  biobank  is  through  a  medical­care 
setting, there may be findings of immediate significance 
for  the  care  and  welfare  of  the  patient.  Due  to  their 
relationship with a physician, patients in clinical trials are 
usually informed of validated findings of clinical utility. 
This stands in contrast to retrospective biobanks where 
re­contact to ascertain the wishes to receive results (of 
alive  or  deceased  individuals)  is  rare.  In  longitudinal 
populational studies where participants provide data and 
samples  for  future  unspecified  research,  the  no­return 
approach is generally favored, as these studies serve to 
create infrastructures for research not to do research. But 
it remains to be seen whether this no­return approach 
will endure once secondary researchers begin to use the 
biobanks for disease­specific studies. Indeed, the advent 
of  whole  genome  sequencing  ensures  that  pertinent 
findings  of  clinical  significance  will  emerge.  Who  will 
communicate these findings if at all: the biobank itself or 
the researcher using it?
In  the  specific  context  of  stem  cell  research  and 
banking, the scientific, ethical and policy implications of 
mandating return of results have seldom been addressed. 
When  they  have  been,  the  possibility  of  returning 
individual  or  general  research  results  is  part  of  the 
informed consent process. Most policies tend to call for 
stem  cell  banks  to  adopt  protocols  governing  the 
disclosure and management of such information back to 
donors. Examples of the latter are those adopted in the 
USA (the National Academies of Science) [49], Canada 
(the  Interangency  Advisory  Panel  on  Research  Ethics) 
[41], Spain (the National Stem Cell Bank) [50], and the 
UK (the UK Stem Cell Bank) [39]. Overall, the general 
trend is to inform donors that no individual return of 
results will be provided. One could argue that this is the 
best  approach,  as  conflations  of  fundamental  research 
with clinical trials wherein there are usually direct health 
implications  could  create  a  therapeutic  misconception, 
leading  research  participants  to  mistakenly  think  that 
there may be personal benefit after all.
Conclusions
While this overview has attempted to trace the routes 
taken and the lessons learned for stem cell banking by 
comparison with biobanking generally, challenges remain 
for both. The first is perhaps best illustrated by the last 
topic:  the  return  of  results  and  its  Tower  of  Babel 
confusion  concerning  terminology.  Like  the  confusion 
surrounding ‘de­identification’ and anonymization before 
it [51], which was resolved via the International Confer­
ence on Harmonisation rules [52], this area is ripe for 
clarification  via  a  common  lexicon  for  stem  cell 
bankers [53].
Similarly,  and  this  applies  for  all  forms  and  fields  of 
banking, access for research needs to be streamlined and 
simplified. Banking is there to serve research and thereby 
respect the wishes of donors. Multiple and contradictory 
ethics reviews, often repeated again for multicenter or 
inter  national studies, undermine the possibility of creat­
ing transparent and accountable governance mecha  nisms. 
Can there be a trusted third­party central clearance body 
or, at a minimum, a safe harbor or substantially equiva­
lent recognition [54] between countries?
In 2008, the ISCR at the University of Massachusetts 
Medical  School  was  established,  with  the  goal  of 
providing provenance information (scientific, ethical) on 
all  existing  pluripotent  (for  example,  embryonic  and 
induced pluripotent) cell lines generated worldwide. The 
ISCR  is  a  searchable  and  comprehensive  database  of 
published  and  validated  unpublished  information  on 
hESCs  and  other  pluripotent  stem  cell  lines.  Since  its 
inception, the ISCR has already compiled validated data 
from over 500 pluripotent cell lines [23]. Similarly, the 
ISSCR  is  establishing  a  Registry  of  Human  Embryonic 
Stem  Cell  Lines  Provenance  [55],  which  is  an  online 
database providing independent validation of the ethical 
provenance  of  hESC  lines.  Will  any  of  these  entities 
become  such  a  central  clearance  body?  Are  these  two 
examples indicative of the emergence of a more rational 
and co­ordinated approach?
A  model  to  be  considered  may  be  that  of  the  Inter­
national Cancer Genome Consortium, where countries 
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ethical  principles,  procedures  and  general  policies. 
Material transfer agreements are uniform, and researchers 
seeking access must provide proof of local ethics review 
and  institutional  responsibility  for  the  information 
provided.  A  privacy  officer  (subject  to  oversight) 
approves centralized access to a federated international 
database [26].
Finally, another thorny issue, kept under the radar until 
recently, is that of diversity. To truly serve local, national 
and international communities, banks need to be able to 
find missing subpopulations and ethnic groups elsewhere 
so as to be representative of the modern societal mosaic 
as research moves to therapies [56,57]; hence the need 
for international exchange and access so as to accurately 
complete the portrait and truly serve the citizens who 
participate.  Traceability  and  identifiability  issues  pale 
before the enormity of this last challenge, but the public 
dividends  of  investing  in  banking  cannot  otherwise  be 
realized.
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